Clinical Trial: Phase 1b/3 Targeted Alpha-Emitter PRRT RYZ101 (Ac225)
Update 27th Dec 2023. Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio This is a significant acquisition and shows the importance and percevied potential of radioligand therapy (RLT) in the commercial pharma world. BMS is a huge company and they paid a huge price for this alpha-emmitter therapy, probably looking forward to exploiting the vast potential in NET, Prostate and other cancer types being considered for treatment using RLTs. Click on the link below to read more Bristol Myers Squibb - Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio (bms.com) [glossary_dictionary term=""][glossary_thesaurus term=""][glossary_translate term=""]Update…